Evidence map›Paper›PMID 25007849›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2014

Do CSF levels of t-Tau, p-Tau and β₁₋₄₂ amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A ¹²³I-FP-CIT study in the early stages of the disease.

Agostino Chiaravalloti, Alessandro Stefani, Alessandro Fiorentini, Annamaria Lacanfora, Paolo Stanzione, Orazio Schillaci

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Cognitive decline in Parkinson disease.Nature reviews. Neurology · 2017
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Agostino ChiaravallotiDepartment of Biomedicine and Prevention, University Tor Vergata, Viale Oxford 81, 00133, Rome, Italy, agostino.chiaravalloti@gmail.com.
Alessandro Stefani
Alessandro Fiorentini
Annamaria Lacanfora
Paolo Stanzione
Orazio Schillaci
University of Rome Tor Vergata · ITFondazione Santa Lucia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the relationships among cerebrospinal fluid (CSF) levels of t-Tau, p-Tau and Aβ₁₋₄₂ amyloid peptide and (123)I-FP-CIT uptake.

methodsThe study included 58 subjects (31 men and 27 women, age 67 ± 9 years) with a clinical diagnosis of Parkinson disease diagnosed according to the United Kingdom Parkinson Disease Society Brain Bank criteria. All subjects underwent a CSF assay 28 ± 3 days before (123)I-FP-CIT SPECT scanning. The relationships were evaluated by means of linear regression analysis and Pearson correlation.

resultsStriatal (123)I-FP-CIT was positively related to both t-Tau and p-Tau CSF values with low levels of t-Tau and p-Tau being related to a low uptake of (123)I-FP-CIT. In particular, differences with higher statistical significance were found for the striatum that is contralateral to theside mainly affected on clinical examination (P<0.001) [corrected].No significant relationships were found between Aβ₁₋₄₂ amyloid peptide and (123)I-FP-CIT binding.

conclusionThe results of our study suggest that the presynaptic dopaminergic system is more involved in Parkinson disease patients with lower t-Tau and p-Tau CSF values while values of Aβ₁₋₄₂ amyloid peptide seems not to be related to nigrostriatal degeneration in our series.

Indexed as

TropanesAgedAmyloid beta-PeptidesBiomarkersDopamineFemaleHumansMaleParkinson DiseasePeptide FragmentsPhosphorylationtau ProteinsTomography, Emission-Computed, Single-Photon2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropaneAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersDopaminePeptide Fragmentstau ProteinsTropanes

Identifiers

PMID25007849
OpenAlexW2000311037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.